Author Affiliations: Departments of Medical Oncology (Dr Kelly) and Urology (Drs Kelly and Gomella), Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania.
Androgen deprivation therapy (ADT) has been the mainstay for the treatment of advanced prostate cancer for the past 7 decades. Surgical castration (orchiectomy) and the use of estrogens have been largely replaced by the administration of gonadotropin-releasing hormone (GnRH) agonists as the most common form of ADT used today.1,2 GnRH agonists are relatively easy to administer, avoid the well-known cardiovascular risks of estrogens and the psychological trauma of surgical castration, and allow the potential for the androgen blockade to be reversed.1,2
Kelly WK, Gomella LG. Androgen Deprivation Therapy and Competing Risks. JAMA. 2011;306(21):2382–2383. doi:10.1001/jama.2011.1791
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: